Susana Camposano

Massachussetts General Hospital

Boston, Massachusetts - 02114

CLINICAL TRIALS 1
CONDITIONS4
INTERVENTIONS2
SINCE2009

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

April 2009 - January 2014

Sclerosis

Tuberous Sclerosis

Lymphangioleiomyomatosis

Angiomyolipoma

Placebo

Everolimus (Rad001)

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Susana Camposano

Massachussetts General Hospital

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP